No GVK Bioscience trialled drugs under EMA spotlight are sold in Switzerland says Swissmedic

By Gareth Macdonald

- Last updated on GMT

Swissmedic HQ in Bern - no GVK trialled drugs listed in EMA probe sold in Switzerland
Swissmedic HQ in Bern - no GVK trialled drugs listed in EMA probe sold in Switzerland

Related tags European union Switzerland

None of the drugs the EMA wants suspended over concerns about data manipulation at GVK Biosciences are sold in Switzerland says Swissmedic.

The Swiss regulator made the announcement last week after a review prompted by the European Medicines Agency’s (EMA) recommendation​ that hundreds of drugs​ trialled at a GVK site in Hyderabad, India be suspended.

Swissmedic said none of the drugs on the EMA list are sold in the country, although “three preparations with export authorisations were identified.​” The organisation explained that these authorisations are granted for drugs not distributed in Switzerland, but intended exclusively for export.

“After the irregularities were disclosed, Swissmedic initially examined the authorisations granted for generics in Switzerland on the basis of studies by the company GVK Biosciences.

Swissmedic added that: "Around 250 authorisations were checked using active substance lists published by the German Federal Institute for Drugs and Medical Devices (BfArM) and the French National Agency for Medicines and Health Products Safety (ANSM).​”

Norway, Iceland and Switzerland

The Bern-based regulator also said it had checked a further 350 drugs that had been approved in the European Union and Norway and Iceland – which like Switzerland are not in the EU – on the basis of defective GVK bioequivalence studies.

The comprehensive analysis revealed that no corresponding preparations are available on the Swiss market. However, Swissmedic did find three products that have been authorised for distribution abroad.

It added that: “The affected companies have been asked to issue statements on the available documentation. Swissmedic will then take the required measures and, if necessary, suspend or withdraw the authorisations.”

The EMA’s proposal has been sent to the European Commission for the final decision which, if in agreement with the recommendation, will apply to all Member States irrespective of whether or not they have taken interim measures to suspend medicines.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers